Dyslipidemia and the progression of renal disease in chronic renal failure patients

Kidney International

Volumn 68, Issue SUPPL. 99, 2005, Pages

  Cases, Aleix ^a,b   Coll, Elisabet ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Chronic kidney disease; Dyslipidemia; Progression

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT; LIPID;

CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY INJURY; MORBIDITY; MORTALITY; PLEIOTROPY; POST HOC ANALYSIS; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE; BLOOD; FEMALE; MALE; META ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS; DISEASE PROGRESSION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC; LIPIDS; MALE; META-ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 33748305555     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09916.x     Document Type: Conference Paper

References (71)

1. STEFANOVIC V, MILOJKOVIC M: Treatment of dyslipidemia in chronic kidney disease. Int J Artif Organs 27:821-827, 2004
2. MOOREHEAD JF, CHAN MK, EL-NAHAS M, VARGHESE Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet II:1309-1311, 1982
3. KEANE WF, KASISKE BM, O'DONNELL MP: Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis. Am J Nephrol 8:261-271, 1988
4. JOLES JA, KUNTER U, JANSSEN U, et al: Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11:669-683, 2000
5. BLANCO S, VAQUERO M, GOMEZ-GUERRERO C, et al: Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity and mild hypertension. Am J Hypertens 18:557-565, 2005
6. ABRASS CK: Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46-53, 2004
7. BUSSOLATI B, DEREGIBUS MC, FONSATO V, et al: Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating phosphatidylinositol 3-kinase/AKT-signalling pathway. J Am Soc Nephrol 16:1936-1947, 2005
8. MUNTNER P, CORESH J, SMITH JC, et al: Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk In Communities. Kidney Int 58:293-301, 2000
9. SCHAEFFNER ES, KURTH T, CURHAN GC, et al: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14:2084-2091, 2003
10. FOX CS, LARSON MG, LEIP EP, CULLETON B: Predictors of new onset kidney disease in a community-based population. JAMA 291:844-850, 2004
11. MANTTARI M, TIULA E, ALIKOSKI T, et al: Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26:670-675, 1995
12. HSU CY, BATES DW, KUPERMAN GJ, CURHAN GC: Diabetes, haemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 36:272-281, 2000
13. SEGURA J, CAMPO C, GIL P, et al: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 15:1616-1622, 2004
14. RAVID M, BROSH D, RAVID-SAFRAN D, et al: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 158:998-1004, 1998
15. GALL MA,HOUGAARD P, BORCH-JOHNSEN K, PARVING HH: Risk factors for development of incipient and overt diabetic nephropathy in participants with non-insulin dependent diabetes mellitus: Prospective observational study. Br Med J 314:783-788, 1997
16. ORCHARD TJ, FORREST KY, KULLER LH,BECKER DJ: Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 24:1053-1059, 2001
17. HADJADJ S, DULY-BOUHANICK B, BEKHERRAZ A, et al: Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 30:43-51, 2004
18. KLEIN R, KLEIN BE, MOSS SE, et al: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22:743-751, 1999
19. COLHOUN HM, LEE ET, BENNETT PH, et al: Risk factors for renal failure: The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S46-S53, 2001
20. SOEDAMAH-MUTHU SS, COLHOUN HM, TASKINEN MR, et al: Differences in HDL-cholesterol:apoA-I+apoA-II ratio and apoE phenotype with albuminuric status in type I diabetic patients. Diabetologia 43:1353-1359, 2000
21. WIRTA OR, PASTERNACK AI, MUSTONEN JT, et al: Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant 11:449-456, 1996
22. OUE T, NAMBA M, NAKAJIMA H, et al: Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients-a 10 year follow-up study. Diabetes Res Clin Pract 46:47-55, 1999
23. HUNSICKER LG, ADLER S, CAGGIULA A, et al: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
24. SAMUELSSON O, MULEC H, KNIGHT-GIBSON C, et al: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
25. MASSY ZA, KHOA TN, LACOUR B, et al: Dyslipidemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 14:2392-2397, 1994
26. WASHIO M, OKUDA S, IKEDA M, et al: Hypercholesterolemia and the progression of the renal dysfunction in chronic renal failure patients. J Epidemiol 6:172-177, 1996
27. LOCATELLI F, ALBERTI D, GRAZIANI G, et al: Factors affecting chronic renal failure progression: Results from a multicentre trial. The Northern Italian Cooperative Study Group. Miner Electrolyte Metab. 18:295-302, 1992
28. CAPPELLI P, EVANGELISTA M, BONOMINI M, et al: Lipids in the progression of chronic renal failure. Nephron 62:31-35, 1992
29. CUSICK M, CHEW EY, HOOGWERF B, et al: Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 66:1173-1179, 2004
30. RAVID M, NEUMANN L, LISHNER M: Plasma lipids and the progression of nephropathy in diabetes mellitus type II: Effect of ACE inhibitors. Kidney Int 47:907-910, 1995
31. SOLINI A, PASSARO A, FIORETTO P, et al: Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. J Intern Med 256:30-36, 2004
32. YOKOYAMA H, TOMONAGA O, HIRAYAMA M, et al: Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40:405-411, 1997
33. SMULDERS YM, RAKIC M, STEHOUWER CD, et al: Determinants of progression of microalbuminuria in patients with NIDDM. A prospective study. Diabetes Care 20:999-1005, 1997
34. NIELSEN S, SCHMITZ A, REHLING A, MOGENSEN CE: The clinical course of renal function in NIDDM patients with normo- and microalbuminuria. J Intern Med 241:133-141, 1997
35. KROLEWSKI AS, WARRAM JH, CHRISTLIEB AR: Hypercholesterolemia-a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int (Suppl 45):S125-131, 1994
36. GIORGINO F, LAVIOLA L, CAVALLO PERIN P, et al: Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study. Diabetologia 47:1020-1028, 2004
37. MULEC H, JOHNSEN SA, WIKLUND O, BJORCK S: Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis 22:196-201, 1993
38. METCALF PA, BAKER JR, SCOTT A, et al: Microalbuminuria in a middle-aged population: Effect of obesity, hypertension and hyperlipidemia. Clin Chem 39:1802-1808, 1992
39. HILLEGE HL, JANSSEN WM, BAK AA, et al: Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 249:519-526, 2001
40. HAFFNER SM, GONZALES C, VALDEZ RA, et al: Is microalbuminuria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia 36:1002-1006, 1993
41. CIRILLO M, SENIGALLIESI L, LAURENZI M, et al: Microalbuminuria in non-diabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population study. Arch Intern Med 158:1933-1939, 1998
42. CAMPESE VM, BIANCHI S, BIGAZZI R: Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int (Suppl 71):S10-S13, 1999
43. CROOK ED, THALLAPUREDDY A, MIGDAL S, et al: Lipid abnormalities and renal disease: Is dyslipidemia a predictor of progression of renal disease? Am J Med Sci 325:340-348, 2003
44. KURELLA M, LO JC, CHERTOW GM: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16:2134-2140, 2005
45. TONELLI M, MOYE L, SACKS FM, et al: Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14:1605-1613, 2003
46. COLLINS R, ARMITAGE J, PARISH S, et al: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
47. ATHYROS VG, PAPAGEORGIOU AA, ELISAF M, MIKHAILIDIS DP: Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 19:615-617, 2003
48. LEMOS PA, SERRUYS PW, DE FEYTER P, et al: Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 95:445-451, 2005
49. VIDT DG, CRESSMAN MD, HARRIS S, et al: Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102:52-60, 2004
50. FRIED LF, ORCHARD TJ, KASISKE BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
51. IMAI Y, SUZUKI H, SAITO T, et al: The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and renal function research group. Clin Exp Hypertens 21:1345-1355, 1999
52. BIANCHI S, BIGAZZI R, CAIAZZA A, et al: A controlled prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41:565-570, 2003
53. LEE TM, SU SF, TSAI CH: Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40:67-73, 2002
54. OZSOY RC, KOOPMAN MG, KASTELEIN JJ, ARISZ L: The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis. Clin Nephrol 63:245-249, 2005
55. RABELINK AJ, HENE RJ, ERKELENS DW, et al: Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 335:1045-1046, 1990
56. BUEMI M, ALLEGRA A, CORICA F, et al: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 67:427-431, 2000
57. TONOLO G, CICCARESE M, BRIZZI P, et al: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 20:1891-1895, 1997
58. TONOLO G, MELIS MG, FORMATO M, et al: Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 30:980-987, 2000
59. SASAKI T, KURATA H, NOMURA K, et al: Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 29:156-63, 1990
60. NAKAMURA T, USHIYAMA C, HIROKAWA K, et al: Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol 21:449-454, 2001
61. SHOJI T, NISHIZAWA Y, TOYOKAWA A, et al: Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 59:664-665, 1991
62. NIELSEN S, SCHMITZ O, MOLLER N, et al: Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia. 36:1079-1086, 1993
63. HOMMEL E, ANDERSEN P, GALL MA, et al: Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35:447-451, 1992
64. ZHANG A, VERTOMMEN J, VAN GAAL L, DE LEEUW I: Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 29:189-194, 1995
65. ASSELBERGS FW, DIERCKS GFH, HILLEGE HL, et al: Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110:2809-2816, 2004
66. EPSTEIN M, CAMPESE VM: Pleiotropic effects of 3-hydroxy-emethylglutaryl coenzyme A reductase inhibitors on renal function. Am J Kidney Dis 45:2-14, 2005
67. VAN DIJK MA, KAMPER AM, VAN VEEN S, et al: Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 16:2152-2157, 2001
68. ANSQUER JC, FOUCHER C, RATTIER S, et al: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 45:485-493, 2005
69. TONELLI M, COLLINS D, ROBINS S, et al: Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 44:832-839, 2004
70. WATTS GF, POWRIE JK, O'BRIEN SF, SHAW KM: Apolipoprotein B independently predicts progression of very low levels of proteinuria in insulin-dependent diabetes. Metabolism 45:1101-1107, 1996
71. LAM KS, CHENG IK, JANUS ED, PANG RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38:604-609, 1995